A 56-year old male with type 2 diabetes and stage 3 chronic kidney disease contacted us recently regarding his new prescription for the SGLT2 inhibitor canagliflozin (Invokana)....
Read More »Examining the Risks of Antihyperglycemic Dual and Triple Therapies for T2D
A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.
Read More »Long-Awaited Cardiovascular Efficacy and Safety Results From VERTIS-CV
Results from the VERTIS-CV trial suggest that ertugliflozin is not superior to placebo in reducing MACE but may reduce the rate of hospitalization for heart failure.
Read More »New Approval for Dapagliflozin to Treat Patients with Heart Failure
Beneficial cardiovascular results were consistent across subgroups regardless of diabetes status or medication combinations.
Read More »Preventing Heart Failure With Farxiga
The FDA has given a Fast Track Designation to accelerate study of Farxiga’s effect on reduction in mortality and heart failure after a heart attack.
Read More »SGLT-2 Inhibitor Chart
Our chart can help you choose the best SGLT-2 inhibitor for your particular patient.
Download the SGLT-2 inhibitors chart (PDF format)
Read More »Dapagliflozin a Potential Treatment for Type 1 Patients
The future could hold more treatment options for patients with type 1 diabetes.
Read More »Empagliflozin Produces Liver Fat Reduction in Randomized Control Trial
Could empagliflozin contribute to the early treatment of NAFLD in patients with T2DM?
Read More »CREDENCE Trial – Overlooked Benefits In Preventing CVD
SGLT2 Inhibitors and their use for preventing cardiovascular diseases.
Read More »Canagliflozin for Those on Triple Drug Therapy with Uncontrolled Diabetes
SGLT-2 inhibitors have proved to be successful hypoglycemics, so should they be recommended earlier for those not achieving goal A1c reductions?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.